Ops emphasis lets Pfizer extend product life

Product enhancements and reformulations, opportunities in niche markets and better planning for competition as patents expire are tactics Pfizer is adopting at its 2-year-old Established Products business unit. The manufacturing operation in Portage, MI, works to grow sales of products that face competition from generics.

The most recent investment in the plant--the company's largest manufacturing operation--involves a $100-million modular sterile packaging and freeze-drying facility. It took three years to install and ramp up, will provide automated filling and formulation, and promises to keep a cap on operating costs while product yields remain high.

Pfizer had $10 billion in worldwide sales of off-patent products last year, according to a local press report. The company says it expects the global market for such products to grow to $500 billion by 2015, nearly double the 2006 figure.

Among such products produced in Portage are anti-inflammatory medicine Solu-Medrol, antibacterial treatment Zyvox and cancer treatment Camptosar.

-see the article

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in itsĀ Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.